Magnetic resonance spectroscopy of blood plasma lipoproteins in malignant disease: Methodological aspects and clinical relevance

Anticancer Research

Volumn 16, Issue 3 B, 1996, Pages 1461-1471

  Engan, T ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

13C NMR spectroscopy; 1H NMR spectroscopy; Blood plasma; Breast cancer; Endocrine treatment; Fatty acids; Lipids; Malignant disease

Indexed keywords

LIPOPROTEIN;

CANCER; CANCER HORMONE THERAPY; CANCER RESEARCH; CARBON NUCLEAR MAGNETIC RESONANCE; CONFERENCE PAPER; HUMAN; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

FATTY ACIDS; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS;

EID: 0030037239     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Kvinnsland S: Serum tumour markers in clinical practice. In: Klepp O and Romslo I (eds), Tumor Markers - an Update. Proceedings from the First Meeting on Tumour Markers in Trondheim, Scand J Clin Lab Invest 51(Suppl 206): 1-105, 1991.
2. Hannisdal E: Host markers and cancer prognosis. Thesis. University of Oslo, 1994.
3. Ohsaka A, Yoshikawa K, Matuhasi T: Detection by proton nuclear magnetic resonance of elevated lactate concentration in serums from patients with malignant tumors. Japan J Med Sci Biol 32: 305-309, 1979.
4. Fossel ET, Carr JM, McDonagh J: Detection of malignant tumors: watersuppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 315: 1369-1376, 1986.
5. Ginsberg HN: Lipoprotein physiology and its relationship to atherogenesis. In: LaRosa JC (ed), Endocrinology and Metabolism Clinics of North America, WB Saunders, Philadelphia, 1990, pp 211-228.
6. Levy RI: The plasma lipoproteins: an overview. In: Jamieson GA, Greenwalt TJ (eds). Trace Components of Plasma: Isolation and Clinical Significance, Alan R. Liss, New York, 1976, pp 25-42.
7. ∼oronto, 1990, pp 895-922.
8. Sanders TAB: Polyunsaturated fatty acids and coronary heart disease. In: Betteridge DJ (ed). Bailliere's Clinical Endocrinology and Metabolism: Lipid and Lipoprotein Disorders, Bailliere Tindall, London, Philadelphia, Sydney, Tokyo, Toronto, 1990, pp 877-894.
9. Holmes KT, Mackinnon WB, May GL, Wright LC, Dyne M, Tattersall MHN, Mountford CE and Sullivan D: Hyperlipidemia as a biochemical basis of magnetic resonance plasma test for cancer. NMR Biomed 1: 44-49, 1988.
10. Fossel ET: The NMR blood test for cancer: current status. Cancer Cells 3: 173-182, 1991.
11. Okunieff P, Zietman A, Kahn J, Singer S, Neuringer LJ, Levine RA and Evans FE: Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med 322: 953-958, 1990.
12. Engan T, Krane J, Klepp O and Kvinnsland S: Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer. N Engl J Med 322: 949-953, 1990.
13. 1H NMR spectra of blood plasma: cancer, diet and freezing. NMR Biomed 1: 90-94, 1988.
14. Wilding P, Senior MB, Inubushi T and Ludwick ML: Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy. Clin Chem 34: 505-511, 1988.
15. Buchthal SD, Hardy MA and Brown TR: Assessing the value of identifying the presence of malignant disease in human plasma by proton nuclear magnetic resonance spectroscopy. Am J Med 85: 528-532, 1988.
16. Engan T, Krane J, Klepp O and Kvinnsland S: Nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med 323: 680, 1990.
17. 1H-NMR plasma spectrum in patients following breast surgery. Eur J Surg Oncol 19: 115-122, 1993.
18. Le Moyec L, de Certaines JD and Eugene M: Proton NMR of cancer patient plasma: a critical review of methods and controversial results. In: De Certaines JD (ed), Magnetic Resonance Spectroscopy of Biofluids, World Scient. Pub. Co., London, 1989, pp 121-139.
19. Frankel EN: Lipid oxidation. Prog Lipid Res 19: 1-22, 1980.
20. 13C nuclear magnetic resonance studies of plasma from patients with primary intracranial neoplasms. J Neurosurg 68: 931-937, 1988.
21. Schuhmacher JH, Conrad D, Manke HG, Clorius JH, Matys ER, Hauser H, Zuna I, Maier-Borst W and Hull WE: Investigations concerning the potential for using H NMR relaxometry or high-resolution spectroscopy of plasma as a screening test for malignant lung disease. Magn Reson Med 13: 103-132, 1990.
22. Otvos JD, Jeyarajah EJ and Bennett DW: Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem 37: 377-386, 1991.
23. Chmurny GN, Hilton BD, Halverson D, McGregor GN, Klose J, Issaq HJ, Muschik GM, Urba WJ, Mellini ML, Costello R, Papadopoulos NM, Caporaso N, Smith ICP, Szuba M, Kroft T, Monck M, Saunders JK and Préfontaine M: An NMR blood test for cancer: a critical assessment. NMR Biomed 1: 136-150, 1988.
24. Berger S, Pfluger KH, Etzel WA and Fischer J: Detection of tumors with nuclear magnetic resonance spectroscopy of plasma. Eur J Cancer Clin Oncol 25: 535-543, 1989.
25. Engan T, Krane J and Kvinnsland S: Proton nuclear magnetic resonance spectroscopy measurements of methylene and methyl line widths in plasma: significant variations with extent of breast cancer. duration of pregnancy and aging. NMR in Biomed 4: 142-149, 1991.
26. Fossel ET: Commentary on "Detection of tumors with nuclear magnetic resonance spectroscopy of plasma" by S. Berger, K.-H. Pflüger, WA Etzel, J Fischer. Eur J Cancer Clin Oncol 25: 925-927, 1989.
27. Engan T, Bjerve KS, Høe AL and Krane J: Proton magnetic resonance spectroscopy of fractionated plasma lipoproteins and reconstituted plasma from healthy subjects and patients with cancer. Scand J Clin Lab Invest 52: 393-408, 1992.
28. Engan T, Krane J, Johannessen DC, Lønning PE and Kvinnsland S: Changes in plasma of breast cancer patients during endocrine treatment as evaluated by lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36: 287-297, 1995.
29. Engan T, Bjerve KS, Høe AL and Krane J: Characterization of plasma lipids in patients with malignant disease by C nuclear magnetic resonance spectroscopy and gas liquid chromatography. Blood 85: 1323-1330, 1995.
30. Fontanals-Ferrer N, Serrat-Serrat J, Sorribas-Vivas A, Gonzalez-Garcia C, GonzalezSastre C and Gomez-Gerique J: Quick method of determining lipoproteins, including those of intermediate density, in serum. Clin Chem 34: 1753-1757, 1988.
31. Kissebah AH and Schectman G: Hormones and lipoprotein metabolism. In: Shepherd J (ed), Baillière's Clinical Endocrinology and Metabolism: Lipoprotein Metabolism, Bailliere Tindall, London, Philadelphia, Sydney, Tokyo, Toronto, 1987, pp 699-725.
32. Slack J, Noble N, Meade TW and North WRS: Lipid and lipoprotein concentrations in 1604 men and women in working populations in north-west London. Br Med J 2: 353-356, 1977.
33. Furman RH, Alaupovic P and Howard RP: Effects of androgens and estrogens on serum lipids and the composition and concentration of serum lipoproteins in normolipemic and hyperlipidemic states. Progr Biochem Pharmacol 2: 215-249, 1967.
34. Tyroler HA: Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) Epidemiologic Studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol 54: 14C-19C, 1984.
35. Svanborg A and Vikrot O: Plasma lipid fractions, including individual phospholipids, at various stages of pregnancy. Acta Med Scand 178, fasc. 5: 615-630, 1965.
36. Hillman L, Schonfeld G, Miller JP and Wulff G: Apolipoproteins in human pregnancy. Metabolism 24: 943-952, 1975.
37. Warth MR, Arky RA and Knopp RH: Lipid metabolism in pregnancy. III. Altered lipid composition in intermediate, very low, low, and high-density lipoprotein fractions. J Clin Endocrinol Metab 41: 649-655, 1975.
38. Evans FE, Levine RA and Okunieff PG: Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma. N Engl J Med 321: 1410-1411, 1989.
39. Herring FG, Phillips PS and Pritchard PH: Proton magnetic resonance spectroscopy of plasma from patients with dyslipoproteinemia: identification of factors governing methyl and methylene proton linewidths. J Lipid Res 30: 521-528, 1989.
40. Mims MP, Morrisett JD, Mattioli CA and Gotto AM Jr: Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma. N Engl J Med 320: 1452-1457, 1989.
41. Montes A, Walden CE, Knopp RH, Cheung M, Chapman MB and Albers JJ: Physiologic and supraphysiologic increases in lipoprotein lipids and apoproteins in late pregnancy and postpartum. Possible markers for the diagnosis of "prelipemia". Arteriosclerosis 4: 407-417, 1984.
42. Miller VT: Dyslipoproteinemia in women. In: LaRosa JC (ed), Endocrinology and Metabolism Clinics of North America, W.B. Saunders, Philadelphia, 1990, pp 381-398.
43. Barclay M, Skipski VP, Terebus-Kekish O, Greene EM, Kaufman RJ and Stock CC: Effects of cancer upon high-density and other lipoproteins. Cancer Res 30: 2420-2430, 1970.
44. Nydegger UE and Butler RE: Serum lipoprotein levels in patients with cancer. Cancer Res 32: 1756-1760, 1972.
45. Basu TK and Williams DC: Plasma and body lipids in patients with carcinoma of the breast. Oncology 31: 172-176, 1975.
46. Spiegel RJ, Schaefer EJ, Magrath IT and Edwards BK: Plasma lipid alterations in leukemia and lymphoma. Am J Med 72: 775-782, 1982.
47. Wieczorek AJ, Rhyner C and Block LH: Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans. Proc Natl Acad Sci (Wash.) 82: 3455-3459, 1985.
48. Alexopoulos CG. Blatsios B and Avgerinos A. Serum lipids and lipoprotein disorders in cancer patients: Cancer 60: 3065-3070, 1987.
49. Wright LC, Sullivan DR, Muller M, Dyne M, Tattersall MHN and Mountford CE: Elevated apolipoprotein (a) levels in cancer patients. Int J Cancer 43: 241-244, 1989.
50. McDonagh J, Fossel ET, Kradin RL, Dubinett SM, Laposata M and Hallaq YA: Effects of tumor necrosis factor-oc on peroxidation of plasma lipoprotein lipids in experimental animals and patients. Blood 80: 3217-3226, 1992.
51. Vatten LJ, Bjerve KS, Andersen Aa and Jellum E: Polyunsaturated fatty acids in serum phospholipids and risk of breast cancer: a case-control study from the Janus Serum Bank in Norway. Eur J Cancer 29A: 532-538, 1993.
52. Wood CB, Habib NA, Apostolov K, Thompson A, Barker W, Hershman M and Blumgart LH: Reduction in the stearic to oleic acid ratio in human malignant liver neoplasms. Eur J Surg Oncol 11: 347-348, 1985.
53. Cheeseman KH, Collins M, Proudfoot K, Slater TF, Burton GW, Webb AC and Ingold KU: Studies on lipid peroxidation in normal and tumour tissues. The Novikoff rat liver tumour. Biochem J 235: 507-514, 1986.
54. Mountford CE and Tattersall MHN: Proton magnetic resonance spectroscopy and tumour detection. Cancer Surveys 6: 285-314, 1987.
55. Halliday KR, Fenoglio-Preiser C and Sillerud LO: Differentiation of human tumors from non-malignant tissue by natural-abundance C NMR spectroscopy. Magn Reson Med 7: 384-411, 1988.
56. Macleod RI, Cassidy D, Laker MF and Soames JV: Fatty acid composition of clinically healthy and malignant oral epithelium. J Oral Pathol Med 19: 149-151, 1990.
57. Chaudry A, McClinton S, Moffat LE and Wahle KW: Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 64: 1157-1160, 1991.
58. Fermor BF, Masters JRW, Wood CB, Miller J, Apostolov K and Habib NA: Fatty acid composition of normal and malignant cells and cytotoxicity of stearic, oleic and sterculic acids in vitro. Eur J Cancer 28A: 1143-1147, 1992.
59. Victor TA, Bergman A and Knop RH: Detecting fatty acids of dietary origin in normal and cancerous human breast tissue by C nuclear magnetic resonance spectroscopy. Br J Cancer 68: 336-341, 1993.
60. Tiwari RK, Mukhopadhyay B, Telang NT and Osborne MP: Modulation of gene expression by selected fatty acids in human breast cancer cells. Anticancer Res 11: 1383-1388, 1993.
61. Muscaritoli M, Cangiano C, Cascino A, Ceci F, Giacomelli L, Cardelli-Cangiano P, Mulieri M and Rossi-Fanelli F: Plasma clearance of exogenous lipids in patients with malignant disease. Nutrition 6: 147-151, 1990.
62. Douglas RG and Shaw JHF: Metabolic effects of cancer. Br J Surg 77: 246-254, 1990.
63. Lundholm K, Edstrom S, Ekman L, Karlberg I and Schersten T: Metabolism in peripheral tissues in cancer patients. Cancer Treat Rep 65(Suppl 5): 79-83, 1981.
64. Rosenberg SA, Longo DL and Lotze MT: Principles and applications of biologic therapy. In: DeVita VT Jr, Hellman S and Rosenberg SA (eds), Cancer: Principles and Practice of Oncol, J.B. Lippineott, Philadelphia, 1989, pp 301-347.
65. Bataille R, Boccadoro M, Klein B, Durie B and Pileri A: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733737, 1992.
66. Costantini V and Zacharski LR: The role of fibrin in tumor metastasis. Cancer Metastasis Rev 11: 283-290, 1992.
67. Heinrich PC, Castell JV and Andus T: Interleukin-6 and the acute phase response. Biochem J 265: 621-636, 1990.
68. Karashima S, Kataoka H, Itoh H, Maruyama R and Koono M: Prognostic significance of alpha-1-antitrypsin in early stage of colorectal carcinomas. Int J Cancer 45: 244250, 1990.
69. Zucker S: Anemia in cancer. Cancer Invest 3: 249-260, 1985.
70. Leray G and de Certaines JD: Proton NMR spectroscopy of plasma lipoproteins: A marker of the immune function in cancer disease? Anticancer Res 14: 1839-1852, 1994.
71. Mountford LC, May GL, Mackinnon WB, Gregory P, Holmes KT, Dyne M, Sullivan D and Mountford CE: Tumour evolution in rats monitored by changes to serum and lipoproteins. Invasion Metastasis 11: 332-347, 1991.
72. Gadeholt G, Kruse S, Halsteinslid L and Sletten E: Proton nuclear magnetic resonance spectroscopy of serum lipoproteins in rabbits with implanted VX-2 carcinoma. Eur J Cancer 26: 611-615, 1990.
73. Kruse S, Gadeholt G, Halsteinslid L and Sletten E: Proton nuclear magnetic resonance spectroscopy serum lipoproteins in rabbits with renal and intramuscular VX-2 carcinoma. Effects of treatment. The Cancer Journal 4: 138-114, 1991.
74. Niendorf A, Stang A, Beisiegel U, Peters A, Nagele H, Gebhardt A and Kuse R: Elevated lipoprotein(a) levels in patients with acute myeloblastic leukaemia after successful chemotherapeutic treatment. Clin Investig 70: 683-685, 1992.
75. Alexopoulos CG, Pournaras S, Vaslamatzis M, Avgerinos A and Raptis S: Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol 30: 412-416, 1992.
76. Fossel ET, Hall FM and McDonagh J: C-13 NMR spectroscopy of plasma reduces interference of hypertriglyceridemia in the H-1 NMR detection of malignancy. Application in patients with breast lesions. Breast Cancer Res Treat 18: 99-110, 1991.
77. 1H NMR of plasma for detecting cancer. The effect of trauma on linewidths. NMR in Biomed 2: 66-69, 1989.
78. Bjøro K, Jellum E and Grace D: The detection of malignant tumors by H-1 NMR of plasma. Possible interference of the results in the case of hypertriglyceridemia. SMRM Annual Meeting, New York, 1987, p 60.
79. Hofeler H and Scheulen ME: Monitoring of patients with nonseminomatous testicular cancer by nuclear magnetic resonance spectroscopy of plasma. Eur J Cancer Clin Oncol 25: 1141-1143, 1989.
80. Sletten E, Kvalheim OM, Kruse S, Farstad M and Søreide O: Detection of malignant tumours by multivariate analysis of proton magnetic resonance spectra of serum. Eur J Cancer 26: 615-618, 1990.
81. Fossel ET, Carr JM and McDonagh J: Detection of malignant tumors by nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 316: 1415, 1987.
82. Fossel ET: Nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med 323: 677-679, 1990.
83. Jordan VC: Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15: 125-136, 1990.
84. Merchant TE: The importance of magnetic resonance spectroscopy in surgical oncology. Europ J Surg Oncol 19: 111-114, 1993.
85. 1H NMR lineshape fitting analyses and biochemical lipid analyses of the lipoprotein fractions VLDL. LDL and HDL, and total human blood plasma. NMR Biomed 6: 225-233, 1993.